Already there is evidence (27) that profiling the exosomal mRNA content from treatment-naïve AML patients can reveal the presence of transcripts relevant to AML prognosis (FLT3-ITD, NPM1), treatment (FLT3-ITD, IGF-IR, CXCR4), and the leukemic niche function (IGF-IR, CXCR4, MMP4). This evidence concerns the gene FLT3 and acute myeloid leukemia.